Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Down 56.8% in February

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 14,323 shares, a decrease of 56.8% from the February 12th total of 33,185 shares. Based on an average daily trading volume, of 31,057 shares, the short-interest ratio is currently 0.5 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 31,057 shares, the short-interest ratio is currently 0.5 days.

Neuphoria Therapeutics Trading Up 2.4%

Shares of NASDAQ:NEUP opened at $4.65 on Wednesday. The stock has a market cap of $25.06 million, a PE ratio of -1.05 and a beta of 0.50. The stock’s fifty day simple moving average is $4.14 and its two-hundred day simple moving average is $6.90. Neuphoria Therapeutics has a 1-year low of $3.64 and a 1-year high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its earnings results on Friday, February 13th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21). On average, sell-side analysts forecast that Neuphoria Therapeutics will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NEUP shares. Wall Street Zen cut shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. HC Wainwright dropped their price target on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Neuphoria Therapeutics currently has an average rating of “Hold” and a consensus target price of $21.00.

Institutional Investors Weigh In On Neuphoria Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Neuphoria Therapeutics during the 4th quarter worth approximately $47,000. Ikarian Capital LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $184,000. Boothbay Fund Management LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $54,000. Bridgeway Capital Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth $57,000. Finally, ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth $116,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.